European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies
The global prevalence of cancer is increasing, largely as more patients are living into old age. Therefore, gastroenterologists caring for patients with inflammatory bowel disease [IBD] increasingly are managing patients with cancer, or a previous history of cancer. This often requires joint management with the patient’s oncologist, enabling case-by-case decision-making based on the characteristics and expected evolution of the index cancer. Previously, no European guidelines existed describing the impact of IBD on malignancy. For this reason, the European Crohn’s and Colitis Organisation [ECCO] Guidelines Committee [GuiCom] decided to elaborate a set of Consensus Statements on optimal risk/benefit strategies for treating IBD patients with cancer or a history of cancer. The development of clinical practice guidelines is expensive and time consuming, and it is the Committee’s hope that these statements will facilitate and accelerate future efforts to elaborate formal guidelines, providing useful information on areas for which evidence is lacking and where controlled studies are needed. The strategy used to produce the Consensus Statements involved five steps: 1. Two members of Guicom [VA and RE] identified four main topics that needed to be addressed: a] IBD and solid tumours; b] IBD and skin and haematological malignancies; c] malignancy related to therapy: risk and prevention; and d] management of IBD patients with a history of malignancy. During 2014, calls for participation in the drafting of consensus statements were issued to ECCO members, and selected oncologists known for their expertise and active research in the field were invited to join the Consensus. Participants were selected by the Committee, and four working groups were created, each composed of a chairperson [LE, RE, LB, and VA], two ECCO members including young members [Y-ECCO], and one or two experienced oncologists. The chairmen and their groups elaborated relevant questions on topics dealing with current practice and/or areas of controversy. Participants in the Consensus Process were asked to provide answers to the questions based on evidence from the literature and their own experience [Delphi procedure].1 2. Working in parallel, the four groups conducted a systematic review of the literature on their topic with the appropriate key words. The searches targeted Medline/PubMed and the Cochrane database, as well as other relevant sources. 3. Provisional statements on the group’s topic were drafted by the chairmen. These statements were then reviewed and commented on by members of the working group. With the aid of a web-based platform [www.cpg-development-org], the review process was later extended to applicants not included in the working groups and the ECCO national representatives [see Acknowledgments]. 4. In January 2015, a meeting [chaired by VA and RE] was held in Vienna to revise and approve the statements. Each statement was projected on a screen, discussed, and revised until a consensus was reached by > 80% of the participants at the meeting. The level of evidence supporting each statement was rated in accordance with the recommendations of the Oxford Centre for Evidence-based Medicine.2 In some areas where the level of evidence is generally low, expert opinion was included as appropriate. 5. The final document on each topic was written by the chairperson in conjunction with the members of his working group. Consensus guideline statements in bold are followed by comments on the evidence and opinion. Statements are intended to be read not in isolation but together with the qualifying comments in the accompanying text. The final text was edited by VA and RE to ensure consistency of style and terminology and then submitted to the participants for final approval. In addition, ECCO has diligently maintained a disclosure policy of potential conflicts of interests [CoI]. The conflict of interest declaration is based on a form used by the International Committee of Medical Journal Editors [ICMJE]. The CoI statement is not only stored at the ECCO Office and the editorial office of the Journal of Crohn’s and Colitis [JCC] but also open to public scrutiny on the ECCO website [https://www.ecco-ibd.eu/about-ecco/ecco-disclosures.html], providing a comprehensive overview of potential conflicts of interest of the consensus participants and guideline authors. Patients with IBD are at increased risk of developing colorectal cancer [CRC] (evidence level [EL] 1) which, in the case of ulcerative colitis [UC], varies with the extent and duration of the disease [EL 1], family history of CRC, and the presence/absence of primary sclerosing cholangitis [PSC] [EL 1]. Over the past 35 years, the risk of CRC in patients with IBD has not declined significantly, but the risk of dying from CRC has decreased [EL 1] Two recent meta-analyses of cohort studies have clarified the increased risk of CRC in patients with IBD. For those with Crohn’s disease [CD],3 the excess CRC risk has at the risk for bowel cancer was The excess CRC risk for patients with has at a of young at and colitis were the risk have that is a risk for CRC in IBD those with The risk of CRC is not by to CRC was in patients with and and those with but the was five more to recent of from a for CRC of in patients with IBD. These that the risk of CRC is increased in patients with but not to the extent and not in The risk of CRC is in patients with on [EL and to the patient’s risk are [EL 1]. the risk of CRC, but not that of cancer or cancer of the or in patients have including the recent and guidelines, the of for the and of in patients with IBD. for cancer be in the European Evidence-based Consensus on in that with of the the risk of but other including case that cancer and/or in the [EL patients with IBD are with CRC are CRC CRC in IBD patients is by and cancer at [EL recent in that CRC patients were those with CRC to were also more to have and of and at as well as or In patients with CRC, disease was with CRC for and the risk of in CRC patients with IBD was as as that of patients were CRC patients with IBD also decreased in a CRC patients with IBD were at cancer their with a of and and a of and the of that of CRC The for patients with or were and with patients In in CRC patients were at cancer CRC but and CRC and were with was used to the of CRC patients with and IBD were not these that IBD patients to CRC at no of IBD on has In patients with or but is [EL 1]. in in young have identified as potential risk for of [EL from are a in In a of clinical studies a of patients with cancer, the of cancer related to was In a of patients with and/or only These and and and the at cancer was in patients with and it be with of the disease disease duration years, colitis with inflammatory and of and to be with systematic review of case and and identified of in and well involved cancer the were their years, and years, of the were or and the involved in the active disease be with cancer at the time of [EL is for patients with The and of are not known [EL cancer is with and This and often the In a systematic review of on cancer the duration of the involved was years, and the of cancer was In patients with a in the of for be for patients with of and a or of The risk for in patients with and is of or cancer of the or is a risk for or [EL 1] with has the of for In a of patients with of IBD with and the of at and were and these of the and/or in in cancer of the in and in and this risk for this was in patients In a systematic review of studies and case the prevalence of the or for was case of cancer in the for by their and on their of this case and in the that cancer 1] or for or for with and of the cancer or involved the colorectal is with increased risk of in patients with IBD. identified of in IBD patients The risk was increased in those with colorectal and in those with a history of is evidence to the for of the and in the of at sclerosing In patients with or have on for or cancer, be ECCO guidelines that in patients with risk of be at is is with of the and the the the risk of cancer is in IBD patients In a of patients with the of developing cancer was disease are in and is no evidence that the two are no risk for the development of in IBD patients have The are generally and are for IBD. of is Patients with the bowel are at increased risk for bowel [EL 1]. are the in patients [EL and in of the and a of these are In a recent of clinical the of in increased by a of with to that in in a cohort of of patients with bowel and those for > In these two the for were at and the risk is the risk of developing cancer in duration of disease be with the development of cancer in patients with with the development of cancer in patients and disease young at of and and other studies have to some of these In a and of for > were with a of and in with duration of at or of from the by in the previous In case to in the and disease to be the with risk of cancer. developing a and that are to be for is not evidence to recommendations on primary of in and of but are and to be used for of patients with In patients with on or as a with or as a of a inflammatory from be be useful for but it not has for with a of The and were or be a or or are be with The of cancer be and patients a or that are to Patients with in are at risk for the and the excess risk is by the these and from the and the a and cancer of the and that is increased in patients with but not those with studies have that is increased in patients with as well as those with in patients not have is no evidence to The of on the history of and have not well management of the cancer risk is in patients with of have a of is in patients IBD. are or the the only of primary of have in IBD a of the for a of the in a with in and a in a from the from a with is no evidence of IBD and The risk of cancer in patients with IBD is not increased to the [EL 1]. by cancer that patients are more to of the and skin and is with increased risk of and of cohort studies a of patients with IBD no increased risk of cancer at in the IBD have by cancer and IBD patients have increased risk for cancer of the the the and the as well as for skin cancer of also to be with increased risk of The also patients with to be more to cancer and their risk of developing cancer is risk for these were for the and of IBD for cancer, and disease for no evidence is to these of the and have not to be with Patients with IBD are at increased risk for that IBD is also with excess risk for as a of the of it but have on this IBD patients a of developing haematological with the patients are more to those with are at risk for to the database, the current risk of is and the is for other haematological are as and and and of and that the risk for haematological is increased in IBD but have or not in a cohort of IBD patients and that but not those with were at risk for the and this was of The that the of excess risk by other groups from the that and patients were and as a IBD in of their for developing haematological in and in disease also have to the of the studies are and often primary the of which is known to be increased in IBD patients and the as well as and also from a of cohort studies risk for was in those with were as as members of the to no excess risk was and patients were as a that included IBD patients and of a increased risk of patients The of was increased in patients with but the risk was more in those of for more that included IBD patients and of a increased risk of patients The of was increased in patients with but the risk was more in those of for more the risk for was increased only in patients in a the these that and as one be of in excess risk for haematological the of the two The increased risk of in as with the and with also from a cohort which for The expected case from the for were and for and These are with from which excess risk for in patients with and of a of studies on the cancer risk with increased risk of risk but not of In the risk of was as as that of the that the excess risk is related to to be in patients with the are at increased risk for developing from four that more often expected in patients to the risk of in patients of with This risk of was increased in patients with but not those with These were in with increased risk of and in IBD those with also be that of the In a of was in a cohort of patients with a conducted on patients in of in those with or conducted by the IBD that cancer is the of in IBD but the impact of haematological was not in disease and are risk for haematological in IBD patients [EL and are involved in The increased risk of haematological in patients with that these also a in to where of increased of at of active IBD the of in the development of in of their patients with haematological In addition, the of these IBD patients in are more to have is that for IBD patients from other The risk is increased by and IBD patients haematological are of have also in IBD In the conducted on and IBD patients and and were with the development of also increased the risk to a this from a patients with IBD are also at increased risk of haematological and the development of disease have with which in in the of the the to but also facilitate the development of haematological of the are at risk for developing and by to increased is to a and is also to that patients with haematological often from including The of haematological be for IBD with haematological that are to or and haematological are [EL for of haematological in IBD patients are and of and are be IBD or inflammatory with or in These are also with inflammatory is to in the of the haematological or of active also the of haematological of the and a be and with which is known to with increased in IBD of that other or the disease is in be a of haematological malignancy and appropriate is no or for IBD patients at risk of developing haematological the increased risk in IBD patients of be in young are to has in patients 35 of were that be in these patients or the of IBD patients on are often a the and The be to on and that the active also the risk of haematological The and of haematological in IBD patients are to those in IBD. is in patients of be with and In patients with have to of is IBD is risk for but it the risk of skin and are the in IBD. is with risk of that one in five of the will skin and/or in the of their will and of these will for the studies have of in patients with The risk to be in patients in those with and it to with and and are the in IBD for IBD patients and from the for and the IBD a risk to that of the but a of The risk for was increased in and patients from on IBD patients and The risk of was in the IBD and more in patients with The with in the risk of but not of as with the studies that IBD not the risk for but a be needed to a in as as inflammatory the risk of is a risk for and skin and it also the risk of in it has with risk for and studies that has a in the of the skin the impact of IBD on the risk for developing skin is to in studies including patients with is generally that the risk of the risk of this as The risk is related to in and it with the duration of The risk for skin with is related to which in to a in skin The risk of is related to developing with the risk for is related to skin the development of some skin in IBD that be with to IBD and with to The and are on those for other are on and IBD has The clinical and are to skin in patients and no are for skin is for IBD those The risk for with for IBD patients on is in these patients Patients be to skin The not be to it including those which the be by a but it also be by a or IBD those are and the of and IBD patients have for skin are at risk for and be in these Patients with IBD are at risk for to or or to the of The are as in of primary by a of the in patients with IBD. The risk of cancer related to IBD has in of and from the of Patients with IBD with are at increased risk for cancer is no evidence that the risk of cancer is increased in patients with is by the of of in The the but is and to of cancer in a of to produce of is the for skin also the and/or of that by from and facilitate the of with which the of The is to be for the excess risk of by these studies conducted in IBD that is not with in the risk of these studies were to but the has also in recent studies that were The a conducted the that the risk of but not that of cancer in was increased in current but the of the not of patients to these to into the In the other two the risk with current of cancer in was by with for and IBD The excess risk in the cohort was and was in the The these is related to the that were included the in the but not in the to was not with excess risk of cancer in of these is a by and which on in of has to the cancer in with of studies have the cancer risk with used in IBD. The of patients with these in these studies also used it is to the to In addition, of the studies were not to a in the risk of cancer. The of the that at this were in on from controlled of for the of cancer was in patients with and those have from a more recent systematic review of from controlled which no or groups in of the of the of of from clinical of in IBD was also in no excess risk of cancer in related to but the risk was increased in patients and from cohort and studies also that not the cancer risk in a recent in no evidence that increased the risk of cancer in IBD patients a of the by these current evidence that not the to cancer risk of IBD studies have on the risk of cancer in IBD patients to largely patients with IBD are with this Two studies have at the cancer risk in patients were with at to those used in but was to and are used in a of patients with IBD and for of on the of cancer with these in IBD are is with excess risk of cancer in the The that in with and followed by and other solid as The excess risk of cancer to the of has not well for for This be to and the malignancy risk with is and duration In IBD patients with is excess risk of which be by is no evidence of excess risk of in IBD patients with In a recent of and the for in the studies was increased in IBD patients but not in or patients used these The were by a of to in with of and the for were in patients and in the of The were in IBD patients and for the and In two studies that the potential impact of the for to not to the of is not the risk of for the as In two cohort the risk of in patients and was to that of patients with in studies the of patients on were to of evidence is in the of The risk of in patients with of were also was not the risk for in patients also the risk of and to the of to the of these In the the risk for these in was that of The by that for with and was with increased risk of with of and patients on In of in the increased of in IBD patients to and in those on that is not with excess risk of The of some other studies also that is not with in the risk of or other haematological of the patients with in these studies were also current or in the cohort in 2014, was with for of and of no has at the excess risk of in IBD patients to Patients with have a risk of the but it is to the that the disease to conducted in that the of in patients with was to that expected in the are on the risk for haematological in IBD patients to but of these the is known to excess risk for with to those related to are more to the and and to in the and more of of in patients with IBD has of that are to a] which in with and other the of and the of b] which in from and c] which in the of 35 or with for more by the of be in IBD patients with [EL for that in IBD the of are and by of a In the the clinical of these in is by a in the The requires in this and strategies for or this have These have not in patients with and their not be in clinical be to in IBD The of these be or and are by or of these of the be of the which be with the the risk of to be in young IBD patients are These are that have in young are to of the of and have to In this of the the risk of this form of was at These be by or other of in the IBD known to be at The risk of in young with and be by the duration of the to in the of 35 are to In this of the the risk for was in with and for those with and In the 80% of the of the of The risk be by the duration of in this to years, IBD patients are are at increased risk for but it is not the excess risk is also the risk of is increased by for IBD which and are more other of cancer. is IBD is with increased risk of patients to are at increased risk for with a of are more in the excess risk of in IBD patients with have from studies conducted in the past The has in a which a for in IBD patients of was a increased in studies from In studies were more but the was that in the The of has to increased increased of in skin and also of of the a excess risk of in IBD patients with past to that the of these this requires no risk was in a in the or in a recent of from the that for is with increased risk of from a that the risk for these is also increased in IBD patients to these this was not in a of from a and a from a recent of controlled on The a excess risk of in patients with and but not in those with In of these it is to on the risk of related to are no on the risk of related to in IBD. are no on the risk of related to for IBD. these are with increased risk for in and in other In patients with the risk of is increased in those with but not to be by The of is in The of a recent that the risk of is increased in IBD of the of In two studies that the impact of on skin cancer the of in IBD patients with to was to that expected in the and and for In a with from a database, the of was with increased risk in patients with IBD In the the was The recent systematic in the field of that the risk of in patients with to is that of patients are for but in a of patients with those with a in the of as with the was no of patients with were not with are no on the risk of related to for IBD in solid is excess risk to of including recent review of 35 of experience no risk of related to the used to as IBD is patients be on the of and skin also be for skin and skin and a history of or and family history of skin cancer, and in involved in be into is for a with IBD. the excess risk of skin with [see other and be for in and patients at risk for these to also be in patients with of or skin In and a skin are In patients with also the excess risk of related to and are by a is the patients to be and the of be In the it is to provide at as by a on the of the patient’s risk for skin cancer and and the expected impact of the In IBD current at years, and to > of have identified as risk for cancer and of the In the of is with increased risk of cancer of the that have the of in the of in IBD patients have increased risk of in with IBD to and was in a in a and from a conducted in a excess risk was with in four other studies in a a that included only a of patients to and two studies of one of which also included inflammatory other are the of in IBD. studies the impact of on the risk of in with but were to the risk with the of patients with or with was is to be the for cancer and and These will not be are reviewed in the European Evidence-based Consensus on the and management of in inflammatory bowel in to including are at increased risk for developing those of the and the cancer is is a risk of the of the risk of cancer in IBD patients with has in only one from The risk was increased in current as